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Hepatitis B virus (HBV) infection remains a major global health problem, exacerbated by poor linkage to care. 
We aimed to determine the prevalence of HBV infection, exposure, self-reported vaccination, vaccine-induced 
immunity, disease awareness, and treatment in the United States by birthplace and race/ethnicity during 1999-2016. 
A total of 47,628 adult participants in the National Health and Nutrition Examination Survey who completed HBV 
core antibody (anti-HBc) and surface antigen (HBsAg) tests and 47,618 adults who completed HBV surface anti-
body (anti-HBs) and anti-HBc tests were included in the analysis. HBV infection was defined by positive HBsAg 
and past exposure by positive anti-HBc. Vaccine-mediated immunity was defined by positive anti-HBs and nega-
tive anti-HBc. No significant change in the prevalence of HBV infection was observed between 1999 and 2016 
(P  =  0.442), affecting 0.35% (95% confidence interval [CI], 0.28-0.45) or 0.84 million adults. In contrast, a sig-
nificant decrease in HBV exposure and increase in vaccine-mediated immunity was observed. U.S.-born persons 
had significantly lower prevalence of HBV infection and exposure as well as higher prevalence of vaccine-mediated 
immunity and self-reported vaccination than foreign-born persons. Prevalence of HBV infection was highest in 
non-Hispanic Asians in both foreign- (3.85%; 95% CI, 2.97-4.97) and U.S.-born (0.79%; 95% CI, 0.17-3.59) per-
sons during 2011-2016. Among infected persons, liver disease awareness was only 15.19%, and treatment rate was 
only 4.60%. Conclusion: This study revealed disparities of HBV infection among ethnic/racial groups and between 
U.S.-born and foreign-born persons. Awareness of liver disease and treatment rate among infected persons was dis-
mal. (Hepatology 2020;71:431-443).
Hepatitis B virus (HBV) infection continues to be a global health threat and a leading cause of cirrhosis and primary liver cancer, globally 
affecting approximately 257 million people according 
to the World Health Organization in 2015 and 292 
million people according to the Polaris Observatory 
in 2016.(1,2) In the United States, prior analyses of 
noninstitutionalized persons without adequate sam-
pling of racial/ethnic minorities estimated that there 
was a total of 847,000 persons with HBV infection 
in 2011-2012.(3) However, the total burden has been 
estimated to be as high as 2.2 million in analyses that 
accounted for HBV prevalence in high-risk U.S.-born 
and immigrant populations.(4)
Poor disease awareness and linkage to care may 
contribute to the high disease burden of HBV.(2-4) 
The Racial and Ethnic Approaches to Community 
Health study, which surveyed 28 minority communi-
ties across the United States, reported poor awareness 
and linkage to care among ethnic minorities.(5) Studies 
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from community and academic medical centers have 
also shown suboptimal evaluation and undertreatment 
even among those linked to care.(6-9)
Non-Hispanic Asians are an important ethnic 
minority group with probably the highest disease 
burden from HBV in the United States, yet prior 
iterations of one of the largest national programs for 
the study of the health of adults and children in the 
United States, the National Health and Nutrition 
Examination Survey (NHANES), did not adequately 
sample non-Hispanic Asians. To remedy this defi-
ciency, Asians have been oversampled since 2011 to 
provide more nationally representative data.(10)
Therefore, we aimed to use the NHANES database 
from 1999 to 2016 to provide population estimates 
for HBV infection, exposure, immunity, liver disease 
awareness, liver disease severity, and treatment rates 
for all major racial/ethnic groups including Asian 
Americans and examine the impact of birthplace (U.S. 
vs. foreign born).
participants and Methods
Data SoURCe aND StUDy 
popUlatIoN
Our study used data from NHANES 1999-2016. 
Details of survey design and laboratory methods can 
be found in Supporting Appendix S1. NHANES has 
been approved by the National Center for Health 
Statistics Research Ethics Review Board of the CDC 
and all participants provided written informed con-
sent before participation in NHANES. To deter-
mine the prevalence of HBV exposure and infection, 
we included adult participants aged 18  years and 
older who had completed hepatitis B core antibody 
(anti-HBc) and hepatitis B surface antigen (HBsAg) 
testing. For self-reported vaccination history, we 
included patients who answered questions regarding 
vaccination history in the NHANES questionnaire. 
For vaccine-induced immunity, we identified par-
ticipants who had both hepatitis B surface antibody 
(anti-HBs) and anti-HBc testing. Participant birth-
place was based on self-reporting.
Data eXtRaCtIoN aND 
VaRIaBle DeFINItIoN
analysis of HBV prevalence, exposure, 
Serologic evidence of Vaccine-Mediated 
Immunity, and Self-Reported 
Vaccination History
We defined HBV infection as seropositivity for 
HBsAg and exposure to HBV as seropositivity for 
anti-HBc. Serologic evidence of vaccine-mediated 
immunity was defined as seropositivity for anti-HBs 
and seronegativity for anti-HBc. Those who were 
anti-HBs and anti-HBc reactive were considered as 
having immunity by prior exposure.
For history of self-reported vaccination, we extracted 
data on participant response to the questionnaire 
regarding history of vaccination. Participants who 
responded “yes, all three doses” to the question “have 
you ever received the 3-dose series of the hepatitis B 
vaccine?” were defined as having history of vaccination.
analysis of HBV Disease Severity, 
Concurrent Fatty liver, general Health 
Care Use, awareness of liver Disease, 
and treatment Rate for HBV Infection
We evaluated liver disease severity by liver enzymes 
(aspartate aminotransferase [AST]) and alanine 
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aminotransferase [ALT]) and Fibrosis-4 (FIB-4) 
score.(11) The formula for FIB-4 score is (age*AST 
level)/(platelet count*ALT1/2). We also extracted rel-
evant laboratory data to calculate the United States 
Fatty Liver Index (USFLI) to identify patients with 
concurrent fatty liver.(12) Participants with a USFLI 
>30 were considered to have fatty liver.
Awareness of having a liver disease, general health 
care use, and rate of treatment for HBV infection 
were assessed through the NHANES questionnaire. 
To evaluate participant awareness of liver disease, we 
extracted the response to the survey question “Has a 
doctor or other health professional ever told you that 
you had any kind of liver condition?” This question is 
not specific for HBV infection, but participants who 
were aware of HBV infection would most likely be 
aware that they had a liver condition. The answer to 
this question is binary—either “yes” or “no.”
For participant health care use within the past 
12  months, we extracted the response to the survey 
question “During the past 12  months, how many 
times have you seen a doctor or other health care pro-
fessional about your health at a doctor’s office, a clinic, 
a hospital emergency room, at home, or some other 
place?” Finally, we estimated the rate of anti-HBV 
treatment based on NHANES interviewer review of 
all prescribed medication containers. If no container 
was available at the time of interview, the interviewer 
asked the participant to verbally report the name of 
the medication. A list of HBV antiviral drugs recorded 
in NHANES can be found in Supporting Table S1.
analysis by Race/ethnicity and 
Birthplace
Birthplace of each subject was categorized as U.S. 
born or foreign born. Participants were asked to select 
one of the six racial/ethnic groups that fits them best: 
non-Hispanic white, non-Hispanic black, Mexican 
American, other Hispanic, non-Hispanic Asian, and 
other-multiracial. Data on non-Hispanic Asians were 
only available for 2011 to 2016 survey. Therefore, 
race/ethnicity-specific analyses only included data 
from NHANES 2011-2016.
analysis for time trends
Trends analyses were conducted for 1999-2016. 
In addition, subgroup analyses were conducted by 
combining data for three 6-year periods: 1999-2004, 
2005-2010, and 2011-2016.
StatIStICal aNalySeS
Adjusted prevalence estimates of HBV infection, 
HBV exposure, self-reported vaccination history, and 
hepatitis B vaccine–mediated immunity were calcu-
lated for each NHANES survey cycle, from 1999 to 
2016. Trends analyses were conducted using logistic 
regression, with NHANES survey cycle as the depen-
dent variable. Race/ethnic specific estimates for HBV 
infection, HBV exposure, self-reported vaccination 
history, and hepatitis B vaccine–mediated immunity 
were calculated using data from 2011 to 2016, as 
NHANES only began oversampling for non-Hispanic 
Asians from 2011.
Population estimates for HBV infection, exposure, 
and immunity in the general population were calculated 
using NHANES data from the most recent cycles 2011-
2016, which has adequate sample size for subanalyses on 
race/ethnicity-specific population estimates. In order to 
calculate the population estimates, adjusted prevalence 
estimates were multiplied by population totals from 
the American Community Survey of the U.S. Census 
Bureau averaged over their respective time periods.
Univariate and multivariate logistic regression were 
used to estimate odds ratios relating various partici-
pant characteristics to disease awareness, and multino-
mial logistic regression was used to estimate risk ratios 
relating participant characteristics to health care use. 
All variables that had a P < 0.10 in stepwise forward 
logistic regression, or those that were clinically rele-
vant, were included in the model.
A two-tailed P value of  <  0.05 was considered to 
be statistically significant. Weighted analyses were 
performed using STATA 15.1 (Stata Corporation, 
College Station, TX), which allows appropriate use of 
the NHANES survey weights to project the results of 
the analysis to the noninstitutionalized, general popu-
lation of the United States.
Results
StUDy popUlatIoN
As shown in Fig. 1, of the 92,062 participants in 
NHANES between 1999 and 2016, we excluded 
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38,714 of those aged younger than 18 years. We then 
separated the NHANES participants into three groups 
based on completion of HBsAg, anti-HBc, and both 
anti-HBc and anti-HBs tests. Among the 53,348 par-
ticipants aged 18 years or older, 89.31% (n = 47,650) 
were tested for both HBsAg and anti-HBc; all but 
10 of these were also tested for anti-HBs. Twenty-
two persons were excluded because of missing birth-
place data. In total, we included 35,263 U.S.-born and 
12,365 foreign-born persons who completed HBsAg 
testing and anti-HBc testing and 35,255 U.S.-born 
and 12,363 foreign-born persons in the study analyses.
pReValeNCe oF HBV INFeCtIoN, 
eXpoSURe, SelF-RepoRteD 
VaCCINatIoN HIStoRy, aND 
SeRologIC eVIDeNCe oF 
VaCCINe-MeDIateD IMMUNIty
overall analysis and analysis by 
Birthplace
Overall, 232 (0.49%) persons included in the study 
tested HBsAg positive, of whom 88 were U.S. born 
(37.90%) and 144 were foreign born (62.10%). During 
1999-2016, there was no significant change in the 
prevalence of HBV infection in the general U.S. pop-
ulation, with an adjusted overall prevalence of 0.31% 
(95% confidence interval [CI], 0.20-0.50) during 
1999-2000 and 0.29% (95% CI, 0.18-0.47) during 
2015-2016 (P  =  0.442; Fig. 2A). Since 2011, when 
oversampling of Asians was initiated, HBV prevalence 
was higher among foreign-born versus U.S.-born 
persons. In addition, despite variations in NHANES 
cycles, there were no statistically significant changes 
in HBV prevalence for either U.S.-born (P  =  0.347) 
or foreign-born (P = 0.270) groups (Fig. 2B; Table 1).
We observed a significant decrease in the prevalence 
of HBV exposure from 5.80% (95% CI, 4.51-7.42) 
during 1999-2000 to 4.69% (95% CI, 3.89-5.65) during 
2015-2016 (P  =  0.014; Fig. 2C). However, on sub-
analysis by birthplace, this decrease was observed only 
in U.S.-born persons from 4.22% (95% CI, 3.31-5.36) 
in 1999-2000 to 2.66% (95% CI, 2.13-3.30) in 2015-
2016 (P  < 0.001), but not in the foreign-born group 
(P = 0.437; Fig. 2D; Supporting Table S2).
During 1999-2016, the prevalence of vaccine- 
mediated immunity increased significantly from 
10.8% (95% CI, 9.8-12.0) in 1999-2000 to 23.1% 
(95% CI, 20.8-25.6) in 2015-2016 (P  <  0.001; 
Fig. 2A,C) overall, with increases in both the U.S.-
born (from 11.3% [95% CI, 10.2-12.6] to 23.6% 
[95% CI, 21.1-26.4]; P  <  0.001) and foreign-born 
groups (from 8.5% [95% CI, 6.26-11.3] to 21.0% 
[95% CI, 17.9-24.5]; P < 0.001).
Out of the whole study population of 47,621, a 
total of 33,867 participants (71.12%) did not have 
complete vaccination, with 32,457 participants 
(67.22%) responding “No” to any vaccination and 
1,410 (3.07%) to “less than three doses.” We observed 
a discrepancy in the prevalence of self-reported vac-
cination history and vaccine-mediated immunity by 
serologic results (anti-HBs reactive but anti-HBc 
negative). For example, in 2011-2016, 36.79% (95% 
CI, 35.56-38.04) of participants reported having 
completed the three-dose hepatitis B vaccine series, 
but serologic evidence of vaccine-mediated immu-
nity was observed in only 23.11% (95% CI, 21.96-
24.30; Supporting Tables S3 and S4).
analysis by age, Race/ethnicity, and 
Birthplace among Cohorts Studied in 
2011-2016
The prevalence of HBV infection was lowest among 
the younger age groups and highest among the older 
age groups, with the exception of non-Hispanic blacks, 
whose HBV prevalence did not vary with age (0.54%-
0.75%; P  =  0.905; Fig. 3). Among non-Hispanic 
blacks, HBV prevalence was generally higher in U.S.-
born than in foreign-born persons, except for those in 
the 18-34 age group (Fig. 3, third panel). In contrast, 
among non-Hispanic Asians, the vast majority of per-
sons with HBV infection were foreign born, and this 
was true across all age groups (Fig. 3, sixth panel).
The prevalence of HBV exposure as well as immu-
nity through prior exposure increased with age (Fig. 4). 
As expected, the prevalence of serologic evidence of 
vaccine-mediated immunity was highest in young 
adults and lower in older adults (Fig. 4, gray bar). 
Additional information on race/ethnicity-specific 
prevalence of HBV infection, exposure, and vaccine- 
mediated immunity stratified by various demographic 
variables in foreign-born and U.S.-born partici-
pants can be found in Supporting Tables S5 and S6, 
respectively.
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FIg. 1. Flowchart for cohort selection from NHANES 199-2016.
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population estimates of HBV Infection, 
exposure, and Serologic evidence of 
Vaccine-Mediated Immunity
Population level analyses for the most recent time 
period of 2011-2016 estimated a total of 0.84 mil-
lion (95% CI, 0.67-1.07 million) persons with HBV 
infection, 11.10 million (95% CI, 9.91-12.44 mil-
lion) persons with prior exposure to HBV, and 54.98 
million (95% CI, 52.19-57.87 million) persons with 
vaccine-mediated immunity among the general 
noninstitutionalized U.S. population (Supporting 
Table S7). Supporting Tables S8, S9, and S10 described 
the race/ethnicity-specific population estimates for 
the overall population, the U.S.-born population, and 
the foreign-born population, respectively.
analysis of the HBV-Infected Cohort: 
Demography, Disease Severity, general 
Health Care Use, Disease awareness, 
and treatment Rate
Based on data of the 232 persons with HBV infec-
tion, population estimates on various demographic 
and clinical characteristics of the population infected 
with HBV were calculated and are described in 
Table 2. The mean age was 46.50 ± 15.9 years, 61.29% 
were male, and 56.80% were foreign born. Among the 
FIg. 2. (A,B) Trends in HBV infection (positive HBsAg) and vaccine-mediated immunity (positive anti-HBs with negative anti-HBc), 
1999-2016. (A) Overall and (B) by birthplace. (C,D) Trends in HBV exposure (positive anti-HBc) and vaccine-mediated immunity 
(positive anti-HBs with negative anti-HBc), 1999-2016. (C) Overall and (D) by birthplace.
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(95% CI) P Value
Overall 14,876 0.32 (0.24-0.43) 16,601 0.35 (0.25-0.50) 16,148 0.35 (0.28-0.45) 0.602
Sex
Male 7,121 0.40 (0.28-0.58) 8,094 0.51 (0.33-0.78) 7,835 0.40 (0.28-0.57) 0.926
Female 7,758 0.24 (0.14-0.43) 8,094 0.21 (0.13-0.32) 8,507 0.31 (0.23-0.42) 0.408
Age groups (years)
18-34 5,182 0.35 (0.20-0.64) 5,037 0.29 (0.14-0.58) 4,764 0.30 (0.19-0.47) 0.641
35-49 3,346 0.33 (0.19-0.58) 4,031 0.32 (0.17-0.60) 3,927 0.37 (0.25-0.57) 0.710
50-64 2,804 0.36 (0.20-0.65) 3,731 0.60 (0.39-0.94) 3,981 0.41 (0.26-0.64) 0.898
65+ 3,547 0.18 (0.08-0.45) 3,802 0.16 (0.08-0.34) 3,476 0.35 (0.17-0.70) 0.241
Birthplace
United States 11,528 0.17 (0.12-0.25) 12,503 0.21 (0.13-0.33) 11,232 0.15 (0.10-0.24) 0.706
Foreign 3,351 1.16 (0.75-1.80) 4,098 1.07 (0.62-1.85) 4,916 1.28 (0.95-1.73) 0.675
Race/ethnicity
NH white 7,162 0.08 (0.04-0.17) 7,894 0.18 (0.11-0.31) 6,060 0.11 (0.05-0.24) 0.633
NH black 2,917 1.05 (0.64-1.72) 3,327 0.78 (0.48-1.24) 3,571 0.69 (0.45-1.04) 0.201
Mexican American 3,596 0.03 (0.01-0.15) 3,204 0.06 (0.02-0.23) 2,298 0.17 (0.06-0.50) 0.092
Hispanic 665 0 1,404 0.24 (0.08-0.70) 1,729 0.06 (0.01-0.37) 0.390
NH Asian 0 N/A 0 N/A 1,964 3.41 (2.64-4.39) N/A
Other 539 3.17 (1.95-5.12) 772 2.01 (1.06-3.79) 526 0.40 (0.12-1.30) 0.002
Education level (age 20+)
<High school 4,304 0.59 (0.36-0.98) 4,526 0.36 (0.20-0.64) 3,480 0.49 (0.31-0.80) 0.571
High school 6,555 0.25 (0.17-0.38) 7,934 0.35 (0.22-0.57) 8,008 0.32 (0.24-0.45) 0.331
≥College 2,454 0.28 (0.11-0.68) 3,072 0.37 (0.18-0.75) 3,847 0.32 (0.20-0.52) 0.802
Birthplace and race/ethnicity
United States 11,528 0.17 (0.12-0.25) 12,503 0.21 (0.13-0.33) 11,232 0.15 (0.10-0.24) 0.706
NH white 6,785 0.06 (0.03-0.15) 7,478 0.14 (0.08-0.24) 5,799 0.08 (0.03-0.22) 0.700
NH black 2,638 0.76 (0.46-1.25) 3,018 0.54 (0.30-0.97) 3,153 0.52 (0.32-0.85) 0.312
Mexican 1,611 0 1,279 0.09 (0.01-0.67) 1,032 0.14 (0.03-0.61) 0.207
Hispanic 227 0 415 0.37 (0.08-1.68) 530 0 0.831
NH Asian 0 N/A 0 N/A 291 0.79 (0.17-3.59) N/A
Other 267 1.39 (0.35-5.38) 313 0.91 (0.22-3.65) 427 0.46 (0.14-1.54) 0.255
Foreign 3,351 1.16 (0.75-1.80) 4,098 1.07 (0.62-1.85) 4,916 1.28 (0.95-1.73) 0.675
NH white 377 0.38 (0.12-1.17) 416 1.06 (0.35-3.17) 261 0.64 (0.14-2.93) 0.556
NH black 279 3.84 (1.86-7.76) 309 2.95 (1.13-7.46) 418 1.94 (1.13-3.30) 0.138
Mexican 1,985 0.05 (0.01-0.27) 1,925 0.04 (0.01-0.17) 1,266 0.19 (0.04-0.88) 0.247
Hispanic 438 0 989 0.18 (0.03-0.93) 1,199 0.09 (0.01-0.53) 0.349
NH Asian 0 N/A 0 N/A 1,673 3.85 (2.97-4.97) N/A
Other 272 4.72 (2.59-8.46) 459 2.70 (1.33-5.43) 99 N/A 0.068
Insured 11,596 0.30 (0.20-0.44) 12,542 0.33 (0.22-0.49) 12,737 0.33 (0.26-0.41) 0.699
Private 6,757 0.24 (0.15-0.37) 6,806 0.30 (0.17-0.54) 6,575 0.28 (0.20-0.38) 0.593
Government 4,741 0.40 (0.23-0.71) 5,678 0.38 (0.24-0.61) 6,042 0.41 (0.28-0.61) 0.902
Uninsured 3,100 0.44 (0.28-0.70) 4,041 0.46 (0.24-0.87) 3,386 0.50 (0.29-0.86) 0.758
Pregnant at time of survey 801 0.06 (0.01-0.41) 450 0.82 (0.21-3.21) 169 0 0.527
Poverty-income ratio
<1 2,778 0.50 (0.24-1.03) 3,289 0.37 (0.17-0.78) 3,509 0.51 (0.32-0.82) 0.896
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foreign born persons, non-Hispanic Asian made up 
the largest group (49.84%), followed by non-Hispanic 
black (25.55%). Among U.S.-born persons with HBV 
infection, the non-Hispanic white group made up 
the largest group (49.15%) followed by non-Hispanic 
black (45.53%).
Whereas foreign-born persons carried the majority 
of the HBV disease burden, U.S.-born persons with 
HBV infection were more likely to have elevated ami-
notransferases (ALT or AST >2 × upper limit of nor-
mal) compared with foreign-born persons (13.20% vs. 
3.21%; P = 0.008). There was also a trend for a higher 
prevalence of advanced liver fibrosis in the U.S.-born 
group (6.28% FIB-4 >3.25 vs. 3.04%; P  =  0.070). 
U.S.-born persons were also older and had a higher 
rate of significant alcohol use defined as >1 drink/
day for women and >2 drinks/day for men (37.7% vs. 
22.7%; P = 0.067). However, there was no significant 
difference in the prevalence of fatty liver between the 
U.S.-born and foreign-born groups as assessed by the 
USFLI (26.72% vs. 20.74%; P = 0.484).
Population estimates for liver disease awareness 
rates were based on data from the 191 persons who 
answered the survey question about having been told 
of a liver condition. Disease awareness rate was very 
low overall with only 15.19% of persons who tested 
HBsAg positive reporting having been told they 
had a liver condition by a doctor or other health 
professionals. There were no statistically significant 
differences in the liver disease awareness rate between 
U.S.-born and foreign-born persons with HBV infec-
tion (P  =  0.814; Table 2). In sensitivity analysis for 
disease awareness by time period, we found that there 
was no significant difference in the awareness rate 
among the 71 infected persons in 1999-2006 com-
pared with the 120 persons in 2007-2016 (16.90%, 
95% CI, 8.77-30.09 vs. 13.80, 95% CI, 8.39-21.85; 
P  =  0.61). Notably, the majority of both U.S.-born 
(96.60%) and foreign-born (65.70%) participants with 
HBV infection reported having received care at least 
once in the 12 months preceding the survey. In mul-
tivariable logistic regression (Supporting Table S12), 
after controlling for age, sex, insurance status, race/
ethnicity, birthplace, poverty, and educational levels, 
the only independent predictor for increased disease 
awareness among infected persons was having one or 
more health care visits (versus none) in the previous 
12  months (adjusted odds ratio  =  5.22; P  =  0.042). 
In an alternative model controlling for the same vari-
ables but with further breakdown of the number of 
health care visits in 12  months (1, 2-3, 4 or more 
versus none), we observed that having only one visit 
per year was not a statistically significant predictor for 
higher likelihood of disease awareness (adjusted odds 
ratio  =  3.26; P  =  0.175), whereas there was a trend 
















(95% CI) P Value
≥1 10,835 0.27 (0.19-0.38) 12,024 0.34 (0.23-0.50) 11,248 0.31 (0.22-0.42) 0.575
Military veteran 2,039 0.15 (0.07-0.31) 2,070 0.36 (0.13-0.98) 1,482 0.18 (0.07-0.42) 0.628
Heavy drinker*
Male 1,946 0.35 (0.16-0.75) 2,443 0.46 (0.21-0.97) 2,455 0.26 (0.16-0.43) 0.516
Female 1,796 0.12 (0.34-0.39) 2,261 0.15 (0.05-0.47) 2,332 0.14 (0.06-0.33) 0.828
FIB-4 score
<1.45 11,932 0.29 (0.21-0.42) 12,675 0.32 (0.21-0.48) 11,845 0.27 (0.20-0.37) 0.745
1.45-3.25 2,643 0.40 (0.20-0.80) 3,413 0.52 (0.30-0.89) 3,788 0.60 (0.39-0.91) 0.324
>3.25 304 1.11 (0.41-3.01) 513 0.36 (0.05-2.67) 515 0.70 (0.42-1.18) 0.586
ALT or AST >2 × ULN† 570 1.54 (0.64-3.65) 621 0.68 (0.13-3.39) 554 2.48 (1.26-4.83) 0.734
NAFLD‡ 2,202 0.18 (0.06-0.53) 2,583 0.29 90.12-0.66) 2,365 0.34 (0.17-0.69) 0.334
*Heavy drinker defined as >2 drinks/day for men or >1 drink/day for women.
†AST ULN: 40 U/L; ALT ULN: 35 U/L for males, 25 U/L for females.‡
NAFLD defined by USFLI, USFLI ≥30.
Abbreviations: N/A, not applicable; NAFLD, nonalcoholic fatty liver disease; NH, non-Hispanic; ULN, upper limit of normal.
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P = 0.109), and having ≥4 health care visits in the past 
year was a statistically significant predictor (adjusted 
odds ratio = 19.00; P = 0.004). In multinomial logistic 
regression, older persons, female, U.S.-born, insured, 
and more educated persons were more likely to visit 
a health care facility in the previous 12  months 
(Supporting Table S11).
Of the 28 participants infected with HBV who 
were aware of their liver condition, 8 (26.26%) had 
received or were receiving antiviral treatment, giving 
an overall treatment rate of roughly 5% among all 
infected persons. Data for subanalysis by birthplace 
are shown in Table 2, but the sample sizes for sub-
groups were very small.
Supporting Fig. S1 shows the population estimates 
for HBV infection, awareness, overall treatment, and 
treatment among those aware of infection in this 
NHANES cohort, 1999-2016.
Discussion
Using the NHANES database, we determined that 
the prevalence of HBV infection in the general U.S. 
adult population from 1999 to 2016 remained stable, 
whereas the prevalence of HBV exposure significantly 
decreased and the prevalence of vaccine-mediated 
immunity significantly increased during this period. 
Based on the most recent survey in 2015-2016, the 
prevalence of HBV infection was 0.29%, which 
equated to 0.71 million persons with HBV infection 
among the noninstitutionalized, general U.S. popula-
tion. Overall, U.S.-born and younger persons showed 
a lower prevalence of HBV infection and exposure as 
well as a higher prevalence of vaccine-mediated immu-
nity and self-reported vaccination than foreign-born 
and older persons. There was also a trend for higher 
rate of advanced fibrosis in U.S.-born HBV-infected 
persons compared with the foreign-born group, and 
this could be due to the older age and higher rate of 
significant alcohol use among the U.S.-born cohort.
A very encouraging finding for the U.S.-born 
population was the positive effect that the multi-
faceted efforts to reduce HBV infection (screening 
of pregnant women, universal infant and catch-up 
vaccinations, and screening of blood supply)(13-15) 
had in decreasing HBV exposure. However, despite 
the progress of vaccination coverage in the U.S., we 
found that more than 70% of the general adult pop-
ulation did not have serological evidence of vaccine- 
mediated immunity. Our results are also in line with 
recent reports that approximately 64 million U.S. per-
sons considered to be high risk by the Centers for 
Disease Control and Prevention criteria still had 
undetectable immunity against HBV in 2013-2014 
(69.4%),(16) suggesting that although these efforts are 
FIg. 4. Age-specific prevalence of overall HBV exposure (positive anti-HBc), immunity by prior exposure (positive anti-HBs and 
positive anti-HBc), and vaccine-mediated immunity (positive anti-HBs with negative anti-HBc), 2011-2016.
FIg. 3. Age- and birthplace-specific prevalence of HBV infection (positive HBsAg) by race/ethnicity, 2011-2016. The scale for non-
Hispanic Asian (0-5) is different than those of other racial/ethnic groups (0-1) owing to the high prevalence.
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effective, efforts may need to be specifically targeted 
to those at the highest risk for HBV (foreign born, 
non-Hispanic Asian, adults with high-risk behav-
iors) to bring about a substantial decrease in HBV 
exposure.
Among U.S.-born persons, non-Hispanic blacks 
who were male, 50-64  years of age, heavy drinkers, 
and on government health care insurance were found 
to have the highest prevalence (0.54%) and the high-
est prevalence of exposure on the population level 
(8.35%). Such a finding may be due to a lower use 
of health care and thus a lower chance of HBV vac-
cination.(17,18) Together, these are important findings 
because Asians and blacks with chronic hepatitis B 
are known to have an 11-fold- and 7-fold-higher risk 
for developing hepatocellular carcinoma (HCC) than 
whites, respectively.(17) Furthermore, a recent study 
found poorer survival of black patients with HCC 
compared with white patients.(19) Therefore, more 
efforts are needed to screen these high-risk persons 
for HBV, to enter them into an HCC surveillance 
program using culturally appropriate approaches, and 
to consider them for treatment to prevent long-term 
complications such as HCC.(18) Such a recommenda-
tion would also be in line with the report from a U.S. 
HBV screening surveillance study sponsored by the 
Centers for Disease Control and Prevention in which 
the investigators concluded that persons born in highly- 
HBV-endemic countries (China, Vietnam, Somalia, 
Myanmar, and Laos) should be considered high risk for 
HBV and screened appropriately.(20) Furthermore, we 
would suggest that both providers and at-risk popula-
tions need education and that the use of alerts in elec-
tronic health records or a clinical checklist with place 
taBle 2. Characteristics of persons With HBV Infection (positive HBsag)
Variable Total HBV (n = 232)* U.S. born (n = 88)* Foreign born (n = 144)* P Value†
Age in years (mean ± SD) 46.50 ± 15.90 50.82 ± 14.28 43.2 ± 16.29 0.001
Male 61.29 (53.20-68.81) 61.82 (48.54-73.54) 60.90 (50.3-70.6) 0.913
Race/ethnicity <0.001
NH white 33.96 (24.81-44.50) 49.15 (36.09-62.32) 18.30 (9.60-32.08)
NH black 35.70 (27.55-44.75) 45.53 (33.05-58.59) 25.55 (17.42-35.83)
Mexican American 3.06 (1.26-7.27) 2.34 (0.71-7.40) 3.81 (1.17-11.7)
Other Hispanic 1.90 (0.68-5.16) 1.32 (0.27-6.17) 2.50 (0.66-9.01)
NH Asian 25.38 (19.03-32.99) 1.66 (0.37-7.20) 49.84 (37.65-62.05)
Awareness of liver disease 15.19 (10.11-22.19) 14.40 (7.30-26.44) 15.89 (9.44-25.53) 0.814
Treated among aware 26.26 (10.65-51.53) 49.49 (17.76-81.64) 7.68 (2.01-25.28) 0.021
Treated among all infected 4.60 (2.02-10.16) 7.03 (2.43-18.67) 2.54 (0.87-7.20) 0.158
Income-to-poverty ratio >1 79.17 (71.23-85.37) 82.12 (70.28-89.92) 76.67 (65.97-84.79) 0.416
Treated among  
income-to-poverty ratio >1
4.77 (1.72-12.50) 8.07 (2.44-23.53) 1.40 (0.33-5.84) 0.040
Insurance 75.35 (67.72-81.68) 83.37 (72.22-90.62) 69.25 (57.68-78.82) 0.065
Treated among insured 6.12 (2.69-13.33) 8.39 (2.94-21.70) 3.74 (1.21-10.99) 0.278
FIB-4> 3.25 4.44 (2.51-7.76) 6.28 (2.62-14.32) 3.04 (1.81-5.05) 0.070
% with NAFLD‡ 23.45 (14.69-35.26) 26.72 (13.16-46.72) 20.74 (12.55-32.30) 0.484
ALT or AST> 2 × ULN§ 7.54 (4.16-13.29) 13.20 (6.52-24.90) 3.21 (1.30-7.70) 0.008
Times received health care over past year <0.001
0 21.01 (15.05-28.54) 3.40 (1.34-8.35) 34.30 (24.8-45.18)
1-3 49.49 (41.95-57.11) 55.44 (41.14-68.89) 45.01 (36.96-53.32)
4-9 12.84 (9.06-17.89) 14.33 (8.32-23.57) 11.72 (7.50-17.85)
10+ 16.65 (10.46-25.47) 26.83 (15.28-42.72) 8.98 (4.51-17.08)
Note: Data are presented as proportion (95% CI) unless otherwise indicated.
*Data shown as population estimates derived from 232 infected persons, NHANES 1999-2016.
†P value represents the significant level of the comparison between U.S.-born and foreign-born patients with HBV.
‡NAFLD defined by USFLI, USFLI ≥30.
§AST ULN: 40 U/L; ALT ULN: 35 U/L for males, 25 U/L for females.
Abbreviations: NAFLD, nonalcoholic fatty liver disease; NH, non-Hispanic; ULN, upper limit of normal.
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of birth should be used to improve HBV screening/ 
diagnosis and treatment.(19-21)
The current study also noted that, among HBV-
infected persons, only 15% of patients were aware of 
having a liver disease and only 5% received antivi-
ral therapy; however, among those who were aware, 
almost 25% did receive treatment. We recognize that 
the survey question was not specific for HBV infec-
tion, and it is possible that some participants who did 
not have symptoms of liver disease might be aware 
they were infected but did not consider themselves to 
have a liver disease or did not remember being told 
(recall bias). We also recognize that because of the 
lack of HBV DNA and HBeAg data in NHANES, 
we were not able to identify patients who met indica-
tions for antiviral therapy, so the treatment rate must 
be interpreted with caution and requires further study. 
In addition, our results may not be generalizable given 
our small sample size.(4,21)
In addition to the study limitations noted above, 
we recognize that we could not differentiate between 
acute and chronic HBV infection because we had 
HBsAg results from only one time point, although it 
is likely that the vast majority of persons who tested 
positive in population surveys have a chronic infec-
tion.(22) Moreover, the absence of serologic evidence 
of vaccine-mediated immunity may not mean lack of 
immunity, as some might have had prior vaccination 
with loss of anti-HBs over time, and these persons may 
remain protected on exposure.(23,24) Additionally, this 
study likely underestimates the true prevalence of HBV 
infection in the United States, as NHANES does not 
sample for several high-risk populations such as the 
homeless and incarcerated. Finally, treatment options 
for hepatitis B in earlier years were limited, although 
disease awareness rates did not improve in recent years.
In conclusion, the prevalence of HBV infection 
has remained relatively stable during 1999-2016 
in the civilian population of the United States at 
0.35%, with an estimated 0.84 million infected per-
sons during 2011-2016. There are wide variations 
in the prevalence of HBV infection and exposure 
by age, race/ethnicity, and birthplace. The majority 
of HBV burden occurred in foreign-born persons, 
with non-Hispanic Asian having the highest preva-
lence (3.30%). Meanwhile, non-Hispanic blacks had 
the highest prevalence among U.S.-born persons 
(0.54%). Among persons with HBV infection, aware-
ness of having a liver condition and treatment rate 
were low. To achieve the goal of the Department of 
Health and Human Services to increase the diagno-
sis rate from one-third to two-thirds of persons with 
chronic HBV by 2020(25) and the elimination of HBV 
by 2030, more effort is needed to improve screening 
and disease awareness among providers and high-risk 
groups for HBV infection so as to provide vaccination 
to those who remain unvaccinated and treatment to 
those who require treatment.(16)
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